This inventor holds 4 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Bausch & Lomb Pharma Holdings Corp., Bausch-Lomb Incorporated, Senju Pharmaceutical Co., Ltd.. Active years: 2015-2020.
Company Filing History:
2 out of 3 
1 out of 1,095 
1 out of 229 Years Active: 2015-2020
Title: Innovations by George Baklayan
Introduction
George Baklayan is a notable inventor based in Huntington Beach, California. He has made significant contributions to the field of pharmaceuticals, holding a total of four patents. His work focuses on enhancing the efficacy and delivery of various medicinal compositions.
Latest Patents
Among his latest patents, Baklayan has developed novel compositions that include bepotastine besilate and a corticosteroid. These compositions also feature at least about 0.008% w/v benzalkonium chloride and hydroxypropylmethyl cellulose E15 LV. Additionally, he has worked on formulations and methods that enhance bromfenac penetration into ocular tissue when topically administered. This innovation provides a more effective alternative to the currently available BROMDAY™ formulation while maintaining the convenience of once-daily administration and reducing the bromfenac concentration required for patients.
Career Highlights
Baklayan has had a successful career in the pharmaceutical industry, working with prominent companies such as Bausch & Lomb Pharma Holdings Corp. and Senju Pharmaceutical Co., Ltd. His expertise in developing innovative drug formulations has made a significant impact in the field.
Collaborations
Throughout his career, Baklayan has collaborated with talented individuals, including Angel Padilla and Shirou Sawa. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
George Baklayan's contributions to pharmaceutical innovations demonstrate his commitment to improving patient care through effective drug formulations. His work continues to influence the industry and enhance therapeutic options for patients.